Life sciences · Journal article
Cell Death Discovery · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Homeostatic gene expression programs persist through oncogenesis, creating new malignant states that adapt to therapies. To reveal how fallopian tube epithelia (FTE) cell states transform into intra-tumoral heterogeneity in ovarian high-grade serous carcinoma (HGSC), we analysed treatment-naive tumors ( n = 50) and normal FTE ( n = 14) by single cell transcriptomics, identifying tissue-specific transcriptional modules gained, lost, or conserved through carcinogenesis. Of these, two conserved, opposing modules associated with survival and showed genetic biases, suggesting that oncogenic drivers employ existing epithelial programs. Challenging the cancer stem cell paradigm, a developmentally early oxidative-phosphorylation module was associated with improved survival, whereas the developmentally late MAPK/NF-κB module defined a stable, chemoresistant state that had lost the MHC II antigen presentation of the corresponding normal FTE state. Using these modules to predict perturbations capable of shifting cell-state dynamics, we demonstrate in patient-derived organoid models that restraining ER stress via SERCA2 activation drives a resistant, NF-κB–active phenotype, whereas inhibiting the DNA repair regulator CCDC6 promotes the opposite, platinum-sensitive state. Our study suggests that conserved tissue-of-origin states, rather than de novo cancer states, drive the key cell state dynamic and clinical response heterogeneity of HGSC and can be targeted in vitro to modulate platinum response.